Literature DB >> 9607001

Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function.

J Walker1, D A Leib.   

Abstract

A herpes simplex virus type 1 (HSV-1) recombinant virus deficient in the virion host shutoff (vhs) function was assessed for its ability to function as a live-attenuated vaccine. Protection of mice from wild-type challenge infection and the establishment and reactivation of HSV-1 latency was measured in a mouse ocular model. Challenge virus replication in corneas and trigeminal ganglia was significantly reduced for vaccinated mice. Consistent with these findings, the vaccinated groups showed no clinical signs during acute infection and high levels of virus-specific IgG and neutralizing antibodies were induced. The establishment of and reactivation from latency in trigeminal ganglia from the vaccinated group were also significantly reduced relative to controls. These data suggest that vhs deletion mutants may have significant utility as live-attenuated HSV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607001     DOI: 10.1016/s0264-410x(97)00164-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.

Authors:  Laila Samady; Emanuela Costigliola; Luci MacCormac; Yvonne McGrath; Steve Cleverley; Caroline E Lilley; Jill Smith; David S Latchman; Benny Chain; Robert S Coffin
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1.

Authors:  Huali Jin; Yijie Ma; Zhipeng Yan; Bellur S Prabhakar; Bin He
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  The virion host shutoff protein of herpes simplex virus 1 blocks the replication-independent activation of NF-κB in dendritic cells in the absence of type I interferon signaling.

Authors:  Christopher R Cotter; Won-keun Kim; Marie L Nguyen; Jacob S Yount; Carolina B López; John A Blaho; Thomas M Moran
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 4.  Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?

Authors:  James R Smiley
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

6.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Protection from lethal herpes simplex virus type 1 infection by vaccination with a UL41-deficient recombinant strain.

Authors:  Tetsuo Koshizuka; Ken Ishioka; Takahiro Kobayashi; Kazufumi Ikuta; Tatsuo Suzutani
Journal:  Fukushima J Med Sci       Date:  2016-03-15

8.  mRNA decay during herpes simplex virus (HSV) infections: mutations that affect translation of an mRNA influence the sites at which it is cleaved by the HSV virion host shutoff (Vhs) protein.

Authors:  Lora A Shiflett; G Sullivan Read
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.

Authors:  Timothy Dudek; Lydia C Mathews; David M Knipe
Journal:  Virology       Date:  2007-11-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.